Treatment News : Integrase Inhibitor Dolutegravir Shows Promise in Drug-Resistant HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 16, 2012

Integrase Inhibitor Dolutegravir Shows Promise in Drug-Resistant HIV

Phase III data show that the experimental integrase inhibitor dolutegravir, a combined effort from GlaxoSmithKline, Pfizer and Shionogi, fully suppressed viral loads among 63 percent of people with multi drug-resistant HIV, Bloomberg reports. Announcing the results of their joint VIKING-3 study at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow, ViiV Healthcare said this third of four late-stage trials of dolutegravir sets the stage for regulatory filing by the end of the year.

ViiV tested the dolutegravir in 183 people with multiple antiretroviral (ARV) class resistance, including resistance to other integrase inhibitors—raltegravir and/or elvitegravir. After 24 weeks, 63 percent achieved an undetectable viral load, with only 3 percent discontinuing because of side effects. The most common side effects, each occurring in 5 percent of patients, included diarrhea, nausea and headache.

To read the Bloomberg article, click here.

To read the ViiV press release, click here.

Search: HIV, antiretroviral, dolutegravir, integrase, GlaxoSmith Kline, multi drug-resistant, VIKING-3, Glasgow, ViiV Healthcare, integrase inhibitor, reltegravir, elvitegravir, side effects.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.